leadf
logo-loader
viewIntellipharmaceutics International Inc

Intellipharmaceutics files new drug application for severe pain

Rexista is aimed at managing pain severe enough to require daily, around-the-clock, long-term opioid treatment.

pain_generic.png
The drug combats severe pain

Pharma group Intellipharmaceutics International Inc (NASDAQ:IPCI) has filed a new drug application (NDA) with the powerful US Food and Drug Administration (FDA) so it can market a treatment for severe pain.

Rexista is aimed at managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are not good enough.

Chief executive Dr Isa Odidi told investors: “The NDA submission of Rexista represents a critical milestone and turning point for the company.

"This is our first NDA submission and the first abuse-deterrent oxycodone product candidate we are aware of that not only resists common forms of abuse but provides a preventive tool that may flag early warning of abuse. 

"We are excited about the prospect of Rexista, if approved, having a positive impact in addressing the opioid epidemic."

The firm reckons its abuse-deterrent and overdose prevention technologies are best in class and it is looking forward to further expanding its development program for abuse-deterrent pain and other medications.

"The company has identified potential manufacturing partners and is currently evaluating various manufacturing options for Rexista in the US. We look forward to working with the FDA during their review of our NDA submission," added Odidi.

The abuse-deterrent properties in Rexista are designed to make it unlikable and discourage its misuse through such things as chewing, licking,  inhalation , or injecting.

Quick facts: Intellipharmaceutics International Inc

Price: - -

NASDAQ:IPCI
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Plurilock Security closes over 5 million dollars in financing as company...

Plurilock Security Solutions (CVE: PLUR- OTCQB: PLCKF) CEO Ian L. Paterson joined Steve Darling from Proactive to share news the company has closed their financings bringing in over 5 million dollars including their most recent amount of 1.6 million. Paterson telling Proactive the company,...

2 hours, 25 minutes ago

2 min read